[{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"Cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026.\"","after":"\"Corcept is a cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026.\""}]},{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/companies.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"}]}]